Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | SVP, CHIEF TECHNICAL OFFICER | February 25, 2025 | February 27, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date February 25, 2025 · Filed February 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 173,756 |
Ending reported balance
After 2025-02-27 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2025-02-25 · Sale · Disposed 9,300 · Balance 186,153 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F2: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.54 to $58.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 2 · 2025-02-25 · Sale · Disposed 700 · Balance 185,453 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F3: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.54 to $58.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2025-02-26 · Sale · Disposed 9,400 · Balance 176,053 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F4: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.62 to $58.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2025-02-26 · Sale · Disposed 600 · Balance 175,453 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F5: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.62 to $58.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2025-02-27 · Sale · Disposed 1,597 · Balance 173,856 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F6: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.71 to $58.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2025-02-27 · Sale · Disposed 100 · Balance 173,756 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.
F2: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.54 to $58.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.54 to $58.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.62 to $58.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.62 to $58.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.71 to $58.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2024 Filed Aug 21, 2024 22:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $61.06 | $610,550.00 |
DisclosureSEC source: 0001415889-24-021850 · form4-08212024_100827.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,176 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $60.65 to $61.51. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 20, 2024 Filed Aug 21, 2024 22:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $16.65 | $166,500.00 |
DisclosureSEC source: 0001415889-24-021850 · form4-08212024_100827.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| July 24, 2024 Filed Jul 24, 2024 21:48 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 8,285 | $0.00 Strike: $16.65 | $0.00 |
DisclosureSEC source: 0001415889-24-020055 · form4-07242024_090711.xml · derivative · entry 9 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,861 Underlying: Common Stock · 10,000 shares Expires 2029-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F6 · derivative.exercise_date: This option was granted on February 12, 2019 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| July 24, 2024 Filed Jul 24, 2024 21:48 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 1,715 | $0.00 Strike: $8.11 | $0.00 |
DisclosureSEC source: 0001415889-24-020055 · form4-07242024_090711.xml · derivative · entry 8 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F5 · derivative.exercise_date: This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| July 24, 2024 Filed Jul 24, 2024 21:48 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $55.12 | $551,150.00 |
DisclosureSEC source: 0001415889-24-020055 · form4-07242024_090711.xml · nonDerivative · entry 6 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,176 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F4 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $54.89 to $55.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 24, 2024 Filed Jul 24, 2024 21:48 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 8,285 | $16.65 | $137,945.25 |
DisclosureSEC source: 0001415889-24-020055 · form4-07242024_090711.xml · nonDerivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| July 24, 2024 Filed Jul 24, 2024 21:48 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 1,715 | $8.11 | $13,908.65 |
DisclosureSEC source: 0001415889-24-020055 · form4-07242024_090711.xml · nonDerivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 169,891 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| July 23, 2024 Filed Jul 24, 2024 21:48 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $8.11 | $0.00 |
DisclosureSEC source: 0001415889-24-020055 · form4-07242024_090711.xml · derivative · entry 7 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,715 Underlying: Common Stock · 10,000 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F5 · derivative.exercise_date: This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| July 23, 2024 Filed Jul 24, 2024 21:48 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 5,291 | $55.27 | $292,407.12 |
DisclosureSEC source: 0001415889-24-020055 · form4-07242024_090711.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,176 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $55.08 to $55.50. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 23, 2024 Filed Jul 24, 2024 21:48 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 4,709 | $54.46 | $256,466.27 |
DisclosureSEC source: 0001415889-24-020055 · form4-07242024_090711.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,467 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $54.05 to $54.97. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 23, 2024 Filed Jul 24, 2024 21:48 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $8.11 | $81,100.00 |
DisclosureSEC source: 0001415889-24-020055 · form4-07242024_090711.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 20:17 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $8.11 | $0.00 |
DisclosureSEC source: 0001415889-24-017625 · form4-06202024_080605.xml · derivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,715 Underlying: Common Stock · 10,000 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F3 · derivative.exercise_date: This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 20:17 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $49.43 | $494,260.00 |
DisclosureSEC source: 0001415889-24-017625 · form4-06202024_080605.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,176 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $49.00 to $49.74. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 20:17 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $8.11 | $81,100.00 |
DisclosureSEC source: 0001415889-24-017625 · form4-06202024_080605.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| May 22, 2024 Filed May 22, 2024 21:24 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $8.11 | $0.00 |
DisclosureSEC source: 0001415889-24-014123 · form4-05222024_090507.xml · derivative · entry 6 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,715 Underlying: Common Stock · 10,000 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F4 · derivative.exercise_date: This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| May 22, 2024 Filed May 22, 2024 21:24 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $45.38 | $453,840.00 |
DisclosureSEC source: 0001415889-24-014123 · form4-05222024_090507.xml · nonDerivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,176 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $45.20 to $45.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 22, 2024 Filed May 22, 2024 21:24 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $8.11 | $81,100.00 |
DisclosureSEC source: 0001415889-24-014123 · form4-05222024_090507.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| May 21, 2024 Filed May 22, 2024 21:24 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $8.11 | $0.00 |
DisclosureSEC source: 0001415889-24-014123 · form4-05222024_090507.xml · derivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,715 Underlying: Common Stock · 10,000 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F4 · derivative.exercise_date: This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| May 21, 2024 Filed May 22, 2024 21:24 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $45.16 | $451,640.00 |
DisclosureSEC source: 0001415889-24-014123 · form4-05222024_090507.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,176 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $44.785 to $45.455. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 21, 2024 Filed May 22, 2024 21:24 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $8.11 | $81,100.00 |
DisclosureSEC source: 0001415889-24-014123 · form4-05222024_090507.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| April 17, 2024 Filed Apr 17, 2024 23:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $8.11 | $0.00 |
DisclosureSEC source: 0001415889-24-011058 · form4-04172024_110437.xml · derivative · entry 6 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,715 Underlying: Common Stock · 10,000 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F3 · derivative.exercise_date: This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| April 17, 2024 Filed Apr 17, 2024 23:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $38.49 | $384,890.00 |
DisclosureSEC source: 0001415889-24-011058 · form4-04172024_110437.xml · nonDerivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,176 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $38.275 to $38.785. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 17, 2024 Filed Apr 17, 2024 23:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $8.11 | $81,100.00 |
DisclosureSEC source: 0001415889-24-011058 · form4-04172024_110437.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| April 16, 2024 Filed Apr 17, 2024 23:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $8.11 | $0.00 |
DisclosureSEC source: 0001415889-24-011058 · form4-04172024_110437.xml · derivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,715 Underlying: Common Stock · 10,000 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F3 · derivative.exercise_date: This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| April 16, 2024 Filed Apr 17, 2024 23:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $38.35 | $383,500.00 |
DisclosureSEC source: 0001415889-24-011058 · form4-04172024_110437.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,176 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| April 16, 2024 Filed Apr 17, 2024 23:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $8.11 | $81,100.00 |
DisclosureSEC source: 0001415889-24-011058 · form4-04172024_110437.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| March 26, 2024 Filed Mar 26, 2024 23:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 2,890 | $0.00 Strike: $8.11 | $0.00 |
DisclosureSEC source: 0001415889-24-009158 · form4-03262024_110343.xml · derivative · entry 6 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,715 Underlying: Common Stock · 2,890 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| March 26, 2024 Filed Mar 26, 2024 23:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 292 | $0.00 Strike: $16.78 | $0.00 |
DisclosureSEC source: 0001415889-24-009158 · form4-03262024_110343.xml · derivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 292 shares Expires 2028-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on July 2, 2018 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| March 26, 2024 Filed Mar 26, 2024 23:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 8,436 | $0.00 Strike: $12.07 | $0.00 |
DisclosureSEC source: 0001415889-24-009158 · form4-03262024_110343.xml · derivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,436 shares Expires 2027-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| March 26, 2024 Filed Mar 26, 2024 23:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 2,890 | $8.11 | $23,437.90 |
DisclosureSEC source: 0001415889-24-009158 · form4-03262024_110343.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Represents an acquisition of 2,890 shares by the Reporting Person pursuant to a cash exercise and hold transaction. Read SEC document |
| March 26, 2024 Filed Mar 26, 2024 23:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 292 | $16.78 | $4,899.76 |
DisclosureSEC source: 0001415889-24-009158 · form4-03262024_110343.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents an acquisition of 292 shares by the Reporting Person pursuant to a cash exercise and hold transaction. Read SEC document |
| March 26, 2024 Filed Mar 26, 2024 23:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 8,436 | $12.07 | $101,822.52 |
DisclosureSEC source: 0001415889-24-009158 · form4-03262024_110343.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an acquisition of 8,436 shares by the Reporting Person pursuant to a cash exercise and hold transaction. Read SEC document |
| March 13, 2024 Filed Mar 13, 2024 21:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 3,551 | $0.00 Strike: $8.11 | $0.00 |
DisclosureSEC source: 0001415889-24-007825 · form4-03132024_090313.xml · derivative · entry 8 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,605 Underlying: Common Stock · 3,551 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F5 · derivative.exercise_date: This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| March 13, 2024 Filed Mar 13, 2024 21:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 6,449 | $0.00 Strike: $12.07 | $0.00 |
DisclosureSEC source: 0001415889-24-007825 · form4-03132024_090313.xml · derivative · entry 7 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,436 Underlying: Common Stock · 6,449 shares Expires 2027-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F4 · derivative.exercise_date: This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| March 13, 2024 Filed Mar 13, 2024 21:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $42.27 | $422,730.00 |
DisclosureSEC source: 0001415889-24-007825 · form4-03132024_090313.xml · nonDerivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,558 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $42.00 to $42.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 13, 2024 Filed Mar 13, 2024 21:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 3,551 | $8.11 | $28,798.61 |
DisclosureSEC source: 0001415889-24-007825 · form4-03132024_090313.xml · nonDerivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 166,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| March 13, 2024 Filed Mar 13, 2024 21:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 6,449 | $12.07 | $77,839.43 |
DisclosureSEC source: 0001415889-24-007825 · form4-03132024_090313.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 21:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $12.07 | $0.00 |
DisclosureSEC source: 0001415889-24-007825 · form4-03132024_090313.xml · derivative · entry 6 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,885 Underlying: Common Stock · 10,000 shares Expires 2027-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F4 · derivative.exercise_date: This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 21:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $41.64 | $416,370.00 |
DisclosureSEC source: 0001415889-24-007825 · form4-03132024_090313.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,558 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $41.26 to $42.035. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 21:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $12.07 | $120,700.00 |
DisclosureSEC source: 0001415889-24-007825 · form4-03132024_090313.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 166,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 23:49 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 7,471 | $0.00 Strike: $8.11 | $0.00 |
DisclosureSEC source: 0001415889-24-005756 · form4-02282024_110246.xml · derivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,156 Underlying: Common Stock · 7,471 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F5 · derivative.exercise_date: This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 23:49 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 7,471 | $39.54 | $295,418.28 |
DisclosureSEC source: 0001415889-24-005756 · form4-02282024_110246.xml · nonDerivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,558 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F4 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.37 to $39.80. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 23:49 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 7,471 | $8.11 | $60,589.81 |
DisclosureSEC source: 0001415889-24-005756 · form4-02282024_110246.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 23:49 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 2,529 | $39.56 | $100,044.71 |
DisclosureSEC source: 0001415889-24-005756 · form4-02282024_110246.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,558 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.40 to $39.82. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 23:49 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $39.95 | $399,460.00 |
DisclosureSEC source: 0001415889-24-005756 · form4-02282024_110246.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,087 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.757 to $40.09. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:12 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 18,985 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-005547 · form4-02272024_100206.xml · derivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,985 Underlying: Common Stock · 18,985 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:12 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 19,674 | $0.00 Strike: $40.56 | $0.00 |
DisclosureSEC source: 0001415889-24-005547 · form4-02272024_100206.xml · derivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,674 Underlying: Common Stock · 19,674 shares Expires 2034-02-23 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 23:59 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 4,264 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004477 · form4-02202024_110252.xml · derivative · entry 6 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,789 Underlying: Common Stock · 4,264 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 23:59 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 6,112 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004477 · form4-02202024_110252.xml · derivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,224 Underlying: Common Stock · 6,112 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 23:59 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,160 | $36.10 | $77,976.00 |
DisclosureSEC source: 0001415889-24-004477 · form4-02202024_110252.xml · nonDerivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,087 F2 · shares: The reported disposition of 2,160 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.